PerkinElmer, a multinational listed corporation headquartered in the United States, agreed to acquire Horizon Discovery, a UK gene editing and gene modulation company, for $383m. "One of the key fundamentals for molecular research and drug discovery is being able to knock down a gene or function and explore the results to discover actionable insights and new clinical trial candidates faster. We're excited to team up with Horizon to not only add CRISPR and RNAi capabilities into our existing portfolio, but also to leverage our combined screening and applied genomics solutions to help propel the next phase of cell and gene research for precision medicine. PerkinElmer leads with science and creates total solutions to bring today's leading innovations together for our customers, while also working at the cutting edge of what's next," Prahlad Singh, PhD, PerkinElmer President and CEO.